BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 17594936)

  • 1. Can sorafenib cause hypothyroidism?
    Robinson SI; Hobday TJ; Sathananthan A; Morris JC; McWilliams RR
    J Chemother; 2007 Jun; 19(3):352-3. PubMed ID: 17594936
    [No Abstract]   [Full Text] [Related]  

  • 2. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B
    Nat Rev Urol; 2011 Jan; 8(1):10-1. PubMed ID: 21116300
    [No Abstract]   [Full Text] [Related]  

  • 3. Sorafenib-induced destructive thyroiditis.
    Iavarone M; Perrino M; Viganò M; Beck-Peccoz P; Fugazzola L
    Thyroid; 2010 Sep; 20(9):1043-4. PubMed ID: 20825302
    [No Abstract]   [Full Text] [Related]  

  • 4. Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
    Herden U; Fischer L; Schäfer H; Nashan B; von Baehr V; Sterneck M
    Transplantation; 2010 Jul; 90(1):98-9. PubMed ID: 20606568
    [No Abstract]   [Full Text] [Related]  

  • 5. [Hepatocellular carcinoma - long-term treatable disease].
    Fínek J
    Klin Onkol; 2012; 25(4):287-9. PubMed ID: 22920170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Invasive squamous cell carcinoma and sorafenib in a black patient.
    Donaldson MR; Stetson CL; Smith JL
    Arch Dermatol; 2011 Jan; 147(1):133-4. PubMed ID: 21242415
    [No Abstract]   [Full Text] [Related]  

  • 7. Target therapy for hepatocellular carcinoma: is sorafenib for everybody?
    Daniele B; Di Maio M
    J Clin Gastroenterol; 2009; 43(5):389-90. PubMed ID: 19564813
    [No Abstract]   [Full Text] [Related]  

  • 8. Sorafenib induced thyroiditis in two patients with hepatocellular carcinoma.
    van Doorn L; Eskens FA; Visser TJ; van der Lugt A; Mathijssen RH; Peeters RP
    Thyroid; 2011 Feb; 21(2):197-202. PubMed ID: 21275767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: thyroid function abnormalities in patients receiving VEGF-targeted therapy.
    Rini BI
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):337-8. PubMed ID: 21558996
    [No Abstract]   [Full Text] [Related]  

  • 10. Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting.
    Verset G; Maréchal R; Bali MA; Devière J; Van Laethem JL
    Ann Oncol; 2010 Jun; 21(6):1381-1382. PubMed ID: 20332137
    [No Abstract]   [Full Text] [Related]  

  • 11. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F; Corsello SM; Longo R; Barnabei A; Gasparini G
    Thyroid; 2009 May; 19(5):539-40. PubMed ID: 19416001
    [No Abstract]   [Full Text] [Related]  

  • 12. All that glitters: sorafenib.
    Abbass K; Dewani S; Markert R; Kaplon MK; Baumann MA
    Intern Med; 2011; 50(7):797. PubMed ID: 21467725
    [No Abstract]   [Full Text] [Related]  

  • 13. Pancreatic endocrine tumors: a report on a patient treated with sorafenib.
    Jeong HK; Roh SY; Hong SH; Won HS; Jeon EK; Shin OR; Lee SL; Ko YH
    J Korean Med Sci; 2011 Jul; 26(7):954-8. PubMed ID: 21738352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
    Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
    Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
    [No Abstract]   [Full Text] [Related]  

  • 15. Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.
    Bellini E; Pia A; Brizzi MP; Tampellini M; Torta M; Terzolo M; Dogliotti L; Berruti A
    Ann Oncol; 2011 Apr; 22(4):988-990. PubMed ID: 21321087
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical hypothyroidism in a renal cell carcinoma patient treated with sorafenib.
    Block MS; Kohli M
    Clin Adv Hematol Oncol; 2011 Apr; 9(4):335-8. PubMed ID: 21558995
    [No Abstract]   [Full Text] [Related]  

  • 17. Sorafenib.
    Hasskarl J
    Recent Results Cancer Res; 2010; 184():61-70. PubMed ID: 20072831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
    Greten TF; Manns MP; Malek N
    Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib in advanced hepatocellular carcinoma.
    Spinzi G; Paggi S
    N Engl J Med; 2008 Dec; 359(23):2497-8; author reply 2498-9. PubMed ID: 19052134
    [No Abstract]   [Full Text] [Related]  

  • 20. Acute hepatitis in a patient with cirrhosis and hepatocellular carcinoma treated with sorafenib.
    Llanos L; Bellot P; Zapater P; Pérez-Mateo M; Such J
    Am J Gastroenterol; 2009 Jan; 104(1):257-8. PubMed ID: 19098892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.